DEAR ADVOCATE,

2019 marked a milestone for Research!America: our 30th year working with you, our members and partners, at the intersection of research, innovation, and policy. This past year was a year of terrific accomplishment — highlighted below — as we made progress in making research and innovation for health a higher national priority.

We know there is much more to be done to assure research has the financial and human resources as well as the partnerships and policies to drive medical progress and to deliver better health, economic growth, prosperity, and national security. In the year ahead, we will be working to overcome a very tight budget scenario for federal science agencies as well as policy challenges around such complex issues as foreign government influence, fetal tissue research, and threats to research and innovation that could result in loss of U.S. global leadership. We will stand shoulder to shoulder with the broad science community in making common cause as we do this work.

We also will, as always in election years, be working with our partners to encourage candidates to speak out on the value of research and innovation. This year, based on successes we’ve seen with our social media initiatives, we will feature a social media push to Presidential and Congressional candidates across the political spectrum underscoring the high priority the public places on achieving medical and scientific progress.

ADVOCACY IN ACTION

Together with the collective voice of our members and others we changed the course of history for patients diagnosed with countless diseases. This happens one step at time, meeting by meeting, letter by letter. Here is a snapshot of what we accomplished together in 2019.

- RAISED THE BUDGET CAPS
- PROTECTED FUNDING FOR AHRQ AND FOUGHT FOR REAUTHORIZATION OF PCORI
- SECURED REPEAL OF THE MEDICAL DEVICE TAX
- INCREASED FUNDING FOR NIH, CDC, FDA AND NSF
  - $2.6 BILLION INCREASE FOR NIH IN FY20
  - $636 MILLION INCREASE FOR CDC IN FY20
  - $203 MILLION INCREASE FOR NSF IN FY20
  - $91 MILLION INCREASE FOR FDA IN FY20
- STRENGTHENED OUR PUBLIC HEALTH DISEASE TRACKING CAPABILITIES
We have long kept a finger on the pulse of public sentiment, and we will continue to provide that information to our members, public decision-makers, and the media on a timely and relevant basis.

The theme of this report, “Then, Now, Imagine,” is a message frame we have put to work for years. It is a clear and powerful way to capture progress made possible by our nation’s research ecosystem, and to align research and innovation with the aspirations we all have for a future we rightly imagine when scourges like cancer, Alzheimer’s, heart disease, mental illnesses, and more are consigned to the history books. We are relentless in our commitment to that imagined future, and we know you are as well. Let’s work together in this exciting new decade for research.

With thanks for your support and engagement and in anticipation of our continued partnership this year.

The Honorable
Michael N. Castle
Chair, Research!America

Mary Woolley
CEO and President,
Research!America

In 2019 Research!America:

- Attained 83 million media reach
- Kept a finger on the pulse of public opinion with 4 new surveys
- Released U.S. investments in medical & health R&D detailing public, private, and nonprofit sector funding sources
- Conducted timely real-world evidence roundtables in San Francisco and Boston
- Convened forum on the pivotal role the landmark Bayh-Dole Act plays in the R&D ecosystem
- Led multi-sector effort aimed at increasing access to clinical trials
In 1962, the median survival age for individuals diagnosed with cystic fibrosis (CF) was just ten years. In 1989, a team of pioneering scientists discovered the gene that causes CF, bringing hope to tens of thousands of patients and loved ones.

Research has led to the creation of 13 drugs for CF, including three that treat the underlying causes. Patient engagement supports development of better care. The life expectancy of people with CF who were born between 2014 and 2018 is predicted to be 44 years.

Not just treatments for CF, but a cure that makes CF history.
Straight Talk: 2019 National Health Research Forum

A panel of women leaders in research kicked off the discussions at Research!America’s annual National Health Research Forum. Forum panelists and speakers reflected on the challenges and achievements of the past 30 years and highlighted hopes for the future to maximize the power of science and data to improve health. Special thanks to the 2019 Forum Sponsors and Lead Sponsor, Pfizer.

2019 Advocacy Awards

Leaders in medical, health, and public health research advocacy whose commitment to scientific progress transforms lives of individuals worldwide were honored at Research!America’s Advocacy Awards Dinner. Nearly 500 distinguished leaders in government, patient advocacy, scientific societies, independent research institutes, industry, and academia gathered to pay special tribute to the honorees. Special thanks to the 2019 Advocacy Award Sponsors and Corporate Host, Johnson & Johnson.
ADVOCACY IN ACTION

The Pulse of American Public Opinion

For over 28 years, Research!America has been commissioning surveys to keep a finger on the pulse of public opinion. Our surveys measure crucial topics such as public support for medical, health, and scientific research; Americans’ priorities for political leaders; the importance of America’s global leadership in health research; the visibility and invisibility of science; and related state-level issues. We also stay abreast of cutting-edge concerns such as vaccines, opioid and drug abuse, antimicrobial resistance, and climate change. This data is regularly used in research advocacy efforts with elected officials, press statements, social media, speeches and presentations, congressional testimony, and much more.

HIV

CHANGING THE COURSE OF HISTORY

THEN

At the height of the HIV/AIDS epidemic in the U.S, an estimated 130,400 Americans acquired new HIV infections in 1985 alone. Most cases of HIV/AIDS were fatal.

NOW

Thanks to research discoveries about HIV transmission and treatment, public health efforts, and increased awareness, the number of new HIV diagnoses made in 2018 in the U.S. has decreased to 37,832. Through Active Retroviral Therapy (ART) and pre-exposure prophylaxis (PrEP) treatments, HIV has been transformed into a manageable chronic condition. And new advances have reduced treatments from dozens of pills to just one a day.

IMAGINE

A cure, a vaccine, and eradication of HIV/AIDS worldwide.
How important is it for the President and Congress to assign a high priority to ensuring faster medical progress?

- 53% very important
- 35% somewhat important
- 4% not very important
- 2% not at all important
- 6% not sure

Would you be willing to pay $1 per week more in taxes if you were certain that all of the money would be spent on additional medical research?

- 68% yes
- 17% no
- 15% not sure

SOURCE: A RESEARCH!AMERICA POLL OF U.S. ADULTS CONDUCTED IN PARTNERSHIP WITH ZOGBY ANALYTICS IN JANUARY 2020
Known as the “first molecular disease” sickle cell disease (SCD) was only curable with a bone marrow transplant—a treatment option not available for most patients. The average lifespan for an individual with SCD was 14 years.

Thanks to advances in basic and translational research, gene therapies and gene editing tools, such as CRISPR/Cas9, are becoming possible treatment options for SCD. Individuals with SCD are living into their forties or fifties and beyond.

A world in which SCD is cured with gene therapy.
Fact Sheets

Fact Sheets Available: 100+

In 2019 alone, Research!America released 30 new or updated fact sheets in partnership with the Lasker Foundation. The fact sheet library was visited 10,000 times over the course of the year, making it the 5th most-visited page on Research!America’s site.

“Sepsis is a devastating condition that affects 1.7 million people in the U.S. every year, yet many people know little about what sepsis is. Research!America’s fact sheet highlights the immense toll sepsis takes on our nation and the urgent need for increased national research funding and awareness.”

THOMAS HEYMANN, EXECUTIVE DIRECTOR, SEPSIS ALLIANCE

Science Advocacy: Making Friends for Science

“I found [Mary Woolley’s] talk very compelling. In fact, I already put into action the advice about finding common ground in skepticism. I have a friend who is skeptical of vaccines and using that technique made it much easier for me to calmly discuss the science behind vaccines.”

KELLI F. MALOTT, PHD CANDIDATE, UNIVERSITY OF CALIFORNIA, IRVINE

Civic Engagement Microgrants

Empowered early-career scientists to be involved in local issues through competitive microgrants

The Research!America 2019-2020 Microgrant Initiative, with support in part by the Rita Allen Foundation, provides funding for graduate student groups’ nonpartisan activities focusing on civic engagement, elevating the importance of scientific research, innovation and public health. These programs encourage dialogue between young scientists and local leaders about the roles science and research play in issues important to their communities.

The Virginia Tech Carilion Student Outreach Program has started a new science-focused podcast, “Big Lick of Science.” The group plans to produce a bi-monthly podcast on communicating science to a wide audience.
LEADERS IN ADVOCACY

Board of Directors

OFFICERS

The Hon. Michael N. Castle, Chair
Governor of Delaware (1985-1992)
U.S. Representative (1993-2011)

The Hon. Kweisi Mfume, **Vice Chair
Director, Health Policy Research Consortium
Chief Health Equity Officer, Capital Technologies Informatics Systems

Mary Wooley, President
Chief Executive Officer, Research!America

E. Albert Reece, MD, PhD, MBA, Secretary
Dean, Executive Vice President for Medical Affairs, John Z. and Akiko K. Bowers Distinguished Professor, University of Maryland School of Medicine

Sudip S. Parikh, PhD, Treasurer
Chief Executive Officer, American Association for the Advancement of Science; Executive Publisher, Science Family of Journals

MARY WOOLEY
President and CEO
Research!America

Erin Brown
Communications Associate

Sara Chang
Director of Advocacy Programs

Kimbalyn Clark-Price
Executive Assistant to the President and CEO

Michael Coburn
Executive Vice President and Chief Operating Officer

Ellie Dehoney
Vice President, Policy and Advocacy

GEORGES C. BENJAMIN, MD
Executive Director, American Public Health Association

NANCY BROWN
Chief Executive Officer, American Heart Association

SUSAN DENTZER
Visiting Fellow, Robert J. Margolis, MD, Center for Health Policy, Duke University

VICTOR J. DZAU, MD
President, National Academy of Medicine

SUSAN FITZPATRICK, PhD
President, James S. McDonnell Foundation

JAY A. GERSHEN, DDS, PhD
The Hon. Bart Gordon Partner, K&L Gates LLP
U.S. Representative, (1985-2011)

WILLIAM N. HAIT, MD, PhD
Global Head, Johnson & Johnson Global External Innovation

LARRY HAUSNER, MBA
President, ConStrat

MARY J.C. HENDRIX, PhD
President, Shepherd University

THE HON. RUSH D. HOLT, PhD

ELIZABETH BAKER KEFFER
Partner and Chief Network Officer, BDT & Company

DEBRA R. LAPPIN, JD
Principal, FaegeDrinker Consulting

ALAN I. LEshner, PhD
Chief Executive Officer Emeritus, American Association for the Advancement of Science

JAMES L. MADARA, MD
Chief Executive Officer and Executive Vice President, American Medical Association

LUCINDA MAINE, PhD, RPh
Executive Vice President & Chief Executive Officer, American Association of Colleges of Pharmacy

MARK McCLELLAN, MD, PhD, MPA
Director, Robert J. Margolis, MD, Center for Health Policy, Duke University

Former Administrator, Centers for Medicare and Medicaid Services (2004-2006)

Former Commissioner, Food and Drug Administration (2002-2004)

HERBERT PARDES, MD
Executive Vice Chairman, Board of Trustees, NewYork-Presbyterian Hospital

HAROLD L. PAX, MD, MS
Executive Vice President and Chancellor for Health Affairs, The Ohio State University

GUILLERMO J. PRADO, PhD
Dean, Graduate School; Leonard M. Miller Professor of Public Health Sciences; Director, Division of Prevention Science and Community Health, Miller School of Medicine; University of Miami

Derek K. Rapp
Managing Director, RiverVest Venture Partners

GARY M. REEDY
Chief Executive Officer, American Cancer Society

AMY COMSTOCK RICK, JD
President and Chief Executive Officer, Food and Drug Law Institute

LAING ROGERS
Community Leader

LARRY J. SHAPIRO, MD
Chief Executive Officer, University Health Partners of Hawai‘i

GREGORY SORENSEN, MD
Executive Chairman, IMRIS

KEITH YAMAMOTO, PhD
Professor Emeritus; Vice Chancellor for Science Policy and Strategy; Director, UCSF Precision Medicine; University of California, San Francisco

ELIAS A. ZERHOUNI, MD
Former Director, National Institutes of Health (2002-2008)

CHAIR EMERITUS

The Hon. John Edward Porter
U.S. Representative (1980-2001)

Staff

Mary Wooley
President and CEO

Erin Brown
Communications Associate

Sara Chang
Director of Advocacy Programs

Kimbalyn Clark-Price
Executive Assistant to the President and CEO

Michael Coburn
Executive Vice President and Chief Operating Officer

Ellie Dehoney
Vice President, Policy and Advocacy

Katie Goode
Director, Alliance Development and Membership

Calitlin Grzeskowiak
Science Outreach Coordinator

Jacqueline Lagoy
Policy and Advocacy Operations Coordinator

Aimée Lefever
Director of Operations

Jenny Luray
Vice President of Strategy and Communications

Donna McElvee
Vice President, Alliance Development and Membership

Melissa Patton
Operations and Database Associate

Anna Platt
Senior Manager of Policy and Advocacy

Michelle Reddersen
Controller

Robert Shalett
Director of Communications

HOWARD HUGHES MEDICAL INSTITUTE SCIENCE POLICY FELLOWS

Sarah Ackerman, PhD
Matthew Davidson, PhD
Cassie Ramos, PhD

BURROUGHS WELLCOME FUND INTERNS

Gwendolyn Bogard, PhD
Erin Brown
Sonia Dermer
Avery League
Rebecca Mandt
Anna O’Dea
Stephanie Sawicki
Sonya Sternlieb
Jessica Yan
Anna Zavodszyk
Fuel the next thirty years of research advocacy. Make a gift.
donate.researchamerica.org